Galecto, Inc. — Investor Relations & Filings
Galecto, Inc. is a clinical-stage biotechnology company that develops novel small molecule therapeutics for cancer and severe liver diseases. The company leverages its expertise in galectin biology to create product candidates that modulate central disease pathways. Its pipeline focuses on inhibitors of key proteins such as galectin-3 and LOXL2, which are implicated in fibrosis and cancer progression. In October 2024, Galecto expanded its oncology portfolio by acquiring GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of multiple genetic subsets of acute myeloid leukemia (AML). The company's research also targets other cancers, including melanoma, head and neck squamous cell carcinoma (HNSCC), and hepatocellular carcinoma (HCC). Galecto's mission is to develop safe and effective treatments that significantly improve patient quality of life.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Damora Therapeutics, Inc. (0001800315) (Filer) | 2026-05-04 | English | |
| 8-K - Damora Therapeutics, Inc. (0001800315) (Filer) | 2026-04-20 | English | |
| 4 - Damora Therapeutics, Inc. (0001800315) (Issuer) | 2026-03-25 | English | |
| 4 - Damora Therapeutics, Inc. (0001800315) (Issuer) | 2026-03-25 | English | |
| 4 - Damora Therapeutics, Inc. (0001800315) (Issuer) | 2026-03-25 | English | |
| 4 - Damora Therapeutics, Inc. (0001800315) (Issuer) | 2026-03-25 | English |
Browse filings by year
7 yearsMarket data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AbbVie Inc.
A research-based biopharmaceutical company developing and m…
|
ABBV | US | Manufacturing |
|
AbCellera Biologics Inc.
Discovers and develops antibody-based therapeutics using a …
|
ABCL | CA | Manufacturing |
|
AbClon Inc.
Develops antibody-based therapeutics using CAR-T, NEST, and…
|
174900 | KR | Manufacturing |
|
ABEONA THERAPEUTICS INC.
A clinical-stage biopharma developing cell and gene therapi…
|
ABEO | US | Manufacturing |
|
ABINGDON HEALTH PLC
A CDMO specializing in lateral flow assays, offering develo…
|
ABDX | GB | Manufacturing |
|
ABIONYX Pharma
Develops biotherapies and drug delivery vectors using apoli…
|
ABNX | FR | Manufacturing |
|
ABIVAX
Clinical-stage biotech developing therapeutics for chronic …
|
ABVX | FR | Manufacturing |
|
Abivax S.A.
Clinical-stage biotech developing miRNA therapeutics for in…
|
ABVX | US | Manufacturing |
|
ABL Diagnostics
Develops molecular diagnostic solutions for managing infect…
|
ABLD | FR | Manufacturing |
|
Abliva
Biopharmaceutical company developing medicines for primary …
|
ABLI | SE | Manufacturing |
Galecto, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35406/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35406 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35406 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35406 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35406}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Galecto, Inc. (id: 35406)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.